10-Q: United-Guardian Inc. Reports Strong Second Quarter and First Half 2024 Results Driven by Cosmetic Ingredient Sales

United-Guardian, Inc. saw a significant increase in net sales and profitability in the second quarter and first half of 2024, primarily driven by strong demand for its cosmetic ingredients.

Summary

• United-Guardian, Inc. reported a 28% increase in net sales for the second quarter of 2024, reaching $3,390,205, compared to $2,650,299 in the same period of 2023.
• For the first half of 2024, net sales increased by 27% to $6,645,149, up from $5,220,623 in the first half of 2023.
• The company's net income for the second quarter of 2024 was $956,225, or $0.21 per share, compared to $461,094, or $0.10 per share, in the second quarter of 2023.
• Net income for the first half of 2024 was $1,881,667, or $0.41 per share, compared to $1,217,175, or $0.26 per share, in the first half of 2023.
• The increase in sales was primarily driven by a significant rise in cosmetic ingredient sales, particularly to Ashland Specialty Ingredients (ASI), due to increased demand in China and reduced competition.
• Pharmaceutical sales saw a slight increase in the second quarter but decreased for the first half of 2024 due to supply constraints of Renacidin earlier in the year.
• The company's cost of sales as a percentage of net sales decreased to 46% in the second quarter of 2024 from 54% in the second quarter of 2023, and to 47% for the first half of 2024 from 48% in the first half of 2023.
• Operating expenses increased slightly, while research and development expenses decreased for both the three and six month periods.
• Investment income increased significantly due to a shift towards U.S. Treasury Bills.
• The company declared and paid a dividend of $0.25 per share in the first half of 2024 and a dividend of $0.35 per share was declared and paid in July 2024.

Sentiment

Score: 8

Explanation: The document presents a very positive outlook with strong financial results, particularly in the cosmetic ingredients segment. The company's strategic moves and focus on growth opportunities contribute to a high sentiment score. However, some risks related to supply chain and customer concentration are noted.

Positives

• The company experienced a substantial increase in net sales and net income for both the second quarter and first half of 2024.
• Cosmetic ingredient sales saw significant growth, driven by increased demand in China and reduced competition.
• The company's cost of sales as a percentage of net sales decreased, indicating improved efficiency.
• Investment income increased due to a strategic shift towards U.S. Treasury Bills.
• The company declared and paid a dividend of $0.25 per share in the first half of 2024 and a dividend of $0.35 per share was declared and paid in July 2024.
• Working capital increased by $711,042 since the end of 2023.

Negatives

• Pharmaceutical sales decreased in the first half of 2024 due to supply constraints of Renacidin earlier in the year.
• Sales to some of the company's distributors in the UK and France decreased.
• The current ratio decreased slightly from 8.0 to 1 at December 31, 2023 to 7.7 to 1 at June 30, 2024.

Risks

• The company is exposed to supply chain instability, primarily due to military conflicts in the Middle East, which could impact raw material lead times and shipping costs.
• The company has a concentration of customers, with a few distributors accounting for a large portion of sales and accounts receivable.
• The company relies on a limited number of raw material suppliers and one contract manufacturer for its pharmaceutical product, Renacidin, which could pose a risk if disruptions occur.
• The company faces competition in the marketplace for some of its products, which could impact sales and pricing.
• The company is subject to changes in government drug rebate programs, which could impact its pharmaceutical sales.

Future Outlook

The company anticipates that it will begin manufacturing and reporting sales of its new line of sexual wellness products in the second half of 2024. The company expects to continue to use its cash to make dividend payments, purchase marketable securities, and take advantage of growth opportunities. The company's tax rate is expected to remain at 21% for the current fiscal year.

Management Comments

• The company is working closely with its suppliers regarding lead times and continues to closely monitor the supply chain situation.
• The company is developing new products using natural and environmentally friendly raw materials, which is a priority for many of the company's cosmetic customers.
• The company's management and Board of Directors are continuing to closely monitor the company's investment portfolio and have made and will continue to make any changes they believe may be necessary or appropriate to minimize the future impact on the company's financial position that the volatility of the global financial markets may have.

Industry Context

The company's strong performance in cosmetic ingredients aligns with the growing global demand for natural and sustainable personal care products. The company's focus on developing new products using natural and environmentally friendly raw materials positions it well in this market. The company's entry into the sexual wellness market with its Natrajel line of products also represents a strategic move to diversify its product portfolio and capitalize on a growing market segment.

Comparison to Industry Standards

• United-Guardian's gross margin of approximately 53% for the first half of 2024 is strong compared to many specialty chemical companies, but lower than some high-margin pharmaceutical companies.
• The company's reliance on a few key distributors is similar to other specialty ingredient suppliers, but it also presents a risk.
• The company's investment strategy of shifting to U.S. Treasury Bills is a common approach to manage risk and take advantage of higher interest rates, especially in times of market volatility.
• Compared to companies like Ashland, which is a major distributor for United-Guardian, United-Guardian is a much smaller company with a more focused product portfolio.
• The company's growth in cosmetic ingredients is in line with the broader trend of increased demand for natural and sustainable ingredients in the personal care industry.

Related Party Transactions

• The company made payments of $10,000 and $20,000 to Ken Globus, the company's former President, for consulting services for the threeand six-month periods ended June 30, 2024, respectively.
• The company made payments of $5,250 and $10,750 to the accounting firm PKF O'Connor Davies for accounting and tax services for the threeand six-month periods ended June 30, 2024, respectively. Lawrence Maietta, a partner at PKF, is a director of the company.

Stakeholder Impact

• Shareholders will benefit from the increased profitability and dividend payments.
• Employees may benefit from the company's growth and potential for future opportunities.
• Customers will benefit from the company's focus on developing new and innovative products.
• Suppliers may benefit from the company's increased production and demand for raw materials.
• Creditors will benefit from the company's improved financial position and ability to meet its obligations.

Next Steps

• The company will continue to monitor the supply chain situation and work closely with its suppliers.
• The company will focus on developing new products using natural and environmentally friendly raw materials.
• The company will begin manufacturing and reporting sales of its new line of sexual wellness products in the second half of 2024.
• The company will continue to monitor its investment portfolio and make changes as necessary.
• The company expects to continue to use its cash to make dividend payments, purchase marketable securities, and take advantage of growth opportunities.

Key Dates

Keywords

cosmetic ingredients, pharmaceuticals, medical lubricants, net sales, net income, financial results, supply chain, Renacidin, Lubrajel, dividends, ASI, China